Returns–Not enough quarters yet
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| LBRXLb Pharmaceuticals Inc | $49.4M | 7.8% | +15.4% |
| NRIXNurix Therapeutics Inc | $38.2M | 6.1% | −9.8% |
| IMCRImmunocore Hldgs PLC | $33.8M | 5.4% | +55.8% |
| TRAXFirst Tracks Biotherapeutics | $30.5M | 4.8% | New |
| FDMT4d Molecular Therapeutics In | $29.6M | 4.7% | +71.0% |
| BMRNBiomarin Pharmaceutical Inc | $29.3M | 4.7% | New |
| DSGNDesign Therapeutics Inc | $29.0M | 4.6% | +134.9% |
| XENEXenon Pharmaceuticals Inc | $26.6M | 4.2% | |
| MIRMMirum Pharmaceuticals Inc | $26.1M | 4.2% | −33.0% |
| INSMInsmed Inc | $24.6M | 3.9% | New |
| CYTKCytokinetics Inc | $24.5M | 3.9% | −4.0% |
| SNDXSyndax Pharmaceuticals Inc | $24.3M | 3.9% | +58.2% |
| NGNENeurogene Inc | $22.5M | 3.6% | −8.7% |
| KLRAKailera Therapeutics Inc | $21.7M | 3.4% | New |
| RVMDRevolution Medicines Inc | $21.7M | 3.4% | −52.8% |
| IKTInhibikase Therapeutics Inc | $18.4M | 2.9% | +12.3% |
| INCYIncyte Corp | $17.6M | 2.8% | New |
| AVTXAvalo Therapeutics Inc | $16.5M | 2.6% | New |
| MLTXMoonlake Immunotherapeutics | $14.6M | 2.3% | New |
| FTHFaeth Therapeutics Inc | $12.9M | 2.0% | +312.3% |
| XFORX4 Pharmaceuticals Inc | $12.0M | 1.9% | |
| IRDOpus Genetics Inc | $11.3M | 1.8% | +448.7% |
| Sol-gel Technologies LtdCUSIP M8694L137 | $10.3M | 1.6% | +63.1% |
| AURAAura Biosciences Inc | $10.2M | 1.6% | New |
| IPSCCentury Therapeutics Inc | $10.1M | 1.6% | +68.8% |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| RVMDRevolution Medicines Inc | March 31, 2026 | +92.6% | $21.7M |
| NGNENeurogene Inc | December 31, 2025 | +52.7% | $22.5M |
| MIRMMirum Pharmaceuticals Inc | December 31, 2025 | +48.2% | $26.1M |
| LBRXLb Pharmaceuticals Inc | December 31, 2025 | +45.8% | $49.4M |
| FDMT4d Molecular Therapeutics In | March 31, 2026 | +42.9% | $29.6M |
| DSGNDesign Therapeutics Inc | March 31, 2026 | +36.0% | $29.0M |
| XENEXenon Pharmaceuticals Inc | December 31, 2025 | +34.7% | $26.6M |
| CYTKCytokinetics Inc | March 31, 2026 | +29.3% | $24.5M |
| NRIXNurix Therapeutics Inc | December 31, 2025 | +27.9% | $38.2M |
| XFORX4 Pharmaceuticals Inc | December 31, 2025 | +16.8% | $12.0M |
Sold off last quarter
- PCVXVaxcyte Inc was $38.5M
- DFTXDefinium Therapeutics Inc was $32.9M
- RCUSArcus Biosciences Inc was $22.6M
- IMVTImmunovant Inc was $10.3M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +33.4% | +14.8% |
| March 31, 2026 | +4.8% | −4.6% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Trails Edge Capital Partners, LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2077247&type=13F-HR&dateb=&owner=include&count=40CIK 2077247
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/2077247/000207724726000004/Filed August 14, 2026 · accession 0002077247-26-000004